OBJECTIVES: To evaluate the efficacy and safety of weekly administration of gemcitabine treatment in chemotherapy-naïve patients with advanced biliary tract and gallbladder cancer. PATIENTS AND METHODS: Gemcitabine at a dose of 800 mg/m2 was administered weekly as a 30-min infusion to patients with previously operated, histologically confirmed, metastatic, or unresectable locally advanced cholangiocarcinoma. Treatment was continued until unacceptable toxicity or disease progression. RESULTS: A total of 30 patients (median age 66 years; range 54-72 years) were included in the study. A median of 14 (range, 4-33) weekly doses was administered. Out of 30 patients evaluable for response, nine partial responses were observed (30.0%), while a further 11 patients demonstrated stable disease (36.7%). The median time to disease progression was 7 months (range, 5-34). Overall response rate was superior in patients with cancer of the gallbladder (ORR = 35.7%) compared with those patients with biliary duct cancer (ORR = 27.3%). This correlated to a significantly longer time to progression of 6.4 months (95% confidence interval (CI), 5.6-7.1 months) versus 3.6 months (95% CI, 2.9-4.3 months; p = 0.03) and a significantly better overall survival of 17.1 months (95% CI, 15.8-18.5 months) versus 11.4 months (95% CI, 10.2-12.6 months, p = 0.021). Toxicities were generally mild with only one case of grade 3 neutropenia. There were no cases of febrile neutropenia and no treatment-related deaths. CONCLUSIONS: Weekly administration of gemcitabine provides a safe, well-tolerated, and effective treatment for chemotherapy naïve patients with advanced cholangiocarcinoma, particularly with a gallbladder origin.
OBJECTIVES: To evaluate the efficacy and safety of weekly administration of gemcitabine treatment in chemotherapy-naïve patients with advanced biliary tract and gallbladder cancer. PATIENTS AND METHODS: Gemcitabine at a dose of 800 mg/m2 was administered weekly as a 30-min infusion to patients with previously operated, histologically confirmed, metastatic, or unresectable locally advanced cholangiocarcinoma. Treatment was continued until unacceptable toxicity or disease progression. RESULTS: A total of 30 patients (median age 66 years; range 54-72 years) were included in the study. A median of 14 (range, 4-33) weekly doses was administered. Out of 30 patients evaluable for response, nine partial responses were observed (30.0%), while a further 11 patients demonstrated stable disease (36.7%). The median time to disease progression was 7 months (range, 5-34). Overall response rate was superior in patients with cancer of the gallbladder (ORR = 35.7%) compared with those patients with biliary duct cancer (ORR = 27.3%). This correlated to a significantly longer time to progression of 6.4 months (95% confidence interval (CI), 5.6-7.1 months) versus 3.6 months (95% CI, 2.9-4.3 months; p = 0.03) and a significantly better overall survival of 17.1 months (95% CI, 15.8-18.5 months) versus 11.4 months (95% CI, 10.2-12.6 months, p = 0.021). Toxicities were generally mild with only one case of grade 3 neutropenia. There were no cases of febrile neutropenia and no treatment-related deaths. CONCLUSIONS: Weekly administration of gemcitabine provides a safe, well-tolerated, and effective treatment for chemotherapy naïve patients with advanced cholangiocarcinoma, particularly with a gallbladder origin.
Authors: A Polyzos; G Nikou; A Giannopoulos; A Toskas; N Kalahanis; J Papargyriou; P Michail; A Papachristodoulou Journal: Ann Oncol Date: 1996-08 Impact factor: 32.976
Authors: M Penz; G V Kornek; M Raderer; H Ulrich-Pur; W Fiebiger; A Lenauer; D Depisch; G Krauss; B Schneeweiss; W Scheithauer Journal: Ann Oncol Date: 2001-02 Impact factor: 32.976
Authors: Steven J Cohen; Linus Ho; Sulabha Ranganathan; James L Abbruzzese; R Katherine Alpaugh; Mary Beard; Nancy L Lewis; Susan McLaughlin; André Rogatko; Juan J Perez-Ruixo; Amanda M Thistle; Tom Verhaeghe; Hao Wang; Louis M Weiner; John J Wright; Gary R Hudes; Neal J Meropol Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: H Ulrich-Pur; G V Kornek; M Raderer; K Haider; W Kwasny; D Depisch; R Greul; B Schneeweiss; G Krauss; J Funovics; W Scheithauer Journal: Cancer Date: 2000-06-01 Impact factor: 6.860
Authors: M Ducreux; P Rougier; A Fandi; M C Clavero-Fabri; A L Villing; F Fassone; L Fandi; J Zarba; J P Armand Journal: Ann Oncol Date: 1998-06 Impact factor: 32.976
Authors: Allyson J Ocean; Paul Christos; Joseph A Sparano; Dan Matulich; Andreas Kaubish; Abby Siegel; Max Sung; Maureen M Ward; Nancy Hamel; Igor Espinoza-Delgado; Yun Yen; Maureen E Lane Journal: Cancer Chemother Pharmacol Date: 2010-10-28 Impact factor: 3.333
Authors: John C Mansour; Thomas A Aloia; Christopher H Crane; Julie K Heimbach; Masato Nagino; Jean-Nicolas Vauthey Journal: HPB (Oxford) Date: 2015-08 Impact factor: 3.647
Authors: Susanna V Ulahannan; Osama E Rahma; Austin G Duffy; Oxana V Makarova-Rusher; Metin Kurtoglu; David J Liewehr; Seth M Steinberg; Tim F Greten Journal: Hepat Oncol Date: 2015-01-01
Authors: Jeffrey A Meyerhardt; Andrew X Zhu; Keith Stuart; David P Ryan; Lawrence Blaszkowsky; Nicole Lehman; Craig C Earle; Matthew H Kulke; Pankaj Bhargava; Charles S Fuchs Journal: Dig Dis Sci Date: 2007-06-29 Impact factor: 3.199